Liver Stiffness Measurement is Useful in Predicting Type 2 Diabetes Mellitus Among Nonalcohol Fatty Liver Disease Patients
Yuping Ding,Guiqiang Wang,Quanjun Deng,Mei Yang,Jinghua Li,Zuoyu Wang,Haiyan Niu,Shihai Xia
DOI: https://doi.org/10.2147/dmso.s448626
2024-01-23
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yuping Ding, 1, 2 Guiqiang Wang, 3, 4 Quanjun Deng, 1, 2 Mei Yang, 1, 2 Jinghua Li, 5 Zuoyu Wang, 1, 2 Haiyan Niu, 1, 2 Shihai Xia 1, 2 1 Department of Gastroenterology and Hepatology, Characteristic Medical Center of the Chinese People's Armed Police Force, Tianjin, 300162, People's Republic of China; 2 Tianjin Key Laboratory of Hepatopancreatic Fibrosis and Molecular Diagnosis & Treatment, Tianjin, 300162, People's Republic of China; 3 Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, People's Republic of China; 4 Department of Infectious Diseases, Peking University International Hospital, Beijing, People's Republic of China; 5 Department of Endocrinology and Hematology, Characteristic Medical Center of the Chinese People's Armed Police Force, Tianjin, 300162, People's Republic of China Correspondence: Shihai Xia, Department of Gastroenterology and Hepatology, Characteristic Medical Center of the Chinese People's Armed Police Force, 220, Chenglin Road, Dongli, Tianjin, 300162, People's Republic of China, Email Background: Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are closely related conditions. Aim: This study investigated a group of individuals with NAFLD to evaluate if liver fibrosis, identified by FibroScan, correlated with T2DM. Methods: 154 NAFLD patients obtained FibroScan, liver ultrasonography (US), and a thorough assessment of clinical implications and chemical biomarkers. Results: In comparison to the NAFLD without T2DM group, the hemoglobin A1c(HBA1c)(mmol/mol%), homeostasis model of assessment for insulin resistance index (HOMA-IR), gamma-glutamyl transferase (GGT), fibrosis indices, and liver stiffness measurement (LSM) values were all considerably higher in the NAFLD with T2DM group. Patients with NAFLD and T2DM had considerably lower serum uric acid(SUA) levels than those with NAFLD alone.Those with severe fibrosis (79.3%, 23/29) in the NAFLD group showed a greater frequency of T2DM than those with mild fibrosis (45.6%, 21/46) or no fibrosis (27.85%, 22/79) (P=0.000). LSM value and elements of the metabolic syndrome (MetS) were independent risk factors for incident T2DM among NAFLD patients (OR=1.466, 95% CI [1.139-1.888], P=0.003; and OR=0.273, 95% CI [0.081-0.916], P=0.036). Conclusion: FibroScan can identify significant fibrosis, which is independently linked to a higher prevalence of T2DM. As a result, it is crucial to make use of this technology to predict T2DM in NAFLD patients. Keywords: liver stiffness measurement, NAFLD, T2DM, risk factors, early warning The main characteristic of non-alcoholic fatty liver disease (NAFLD) is excessive fat deposition in the liver. It has a close connection to metabolic syndrome (MetS), whose prevalence has increased as obesity has become more widespread. Type 2 diabetes mellitus (T2DM) and obesity are two metabolic risk factors that are associated with NAFLD, which is defined by 5% hepatocyte steatosis. The exclusion of other chronic liver disorders and excessive alcohol use (over 30 g/day for men and 20 g/day for women) are additional qualifiers. 1 In 2020, a global panel of experts categorized fatty liver as metabolic dysfunction-associated fatty liver disease (MAFLD), changing it from a negative exclusion diagnosis. NAFLD is the most common chronic liver disease worldwide, whereas non-alcoholic steatohepatitis (NASH) is the more severe form of NAFLD that can lead to liver fibrosis and cirrhosis. T2DM is a recognized risk factor for the development of NASH in NAFLD. Thus, the development of T2DM may potentially be influenced by NAFLD and fibrosis. 2,3 It had been determined that patients with NAFLD and T2DM had an approximately 37% global prevalence of NASH and an approximately 17% global prevalence of advanced fibrosis, respectively. 4 NAFLD increases the probability of becoming T2DM. 5,6 The risk of acquiring T2DM at its early starting doubles in patients with NAFLD, despite the fact that NAFLD is present in more than 70% of patients with T2DM. 2,7 The emergence of hyperglycemia and T2DM is the most clear consequence of NAFLD's association with extrahepatic insulin since insulin resistance (IR) and NAFLD are connected. 8 The risk of developing T2DM is higher in patients with NAFLD and extensive fibrosis. 4 Several pharmacological strategies have been evaluated in the treatment of NASH and NAFLD utilizing already available medications such as antidiabetic and anti-obesity medicines.< -Abstract Truncated-
endocrinology & metabolism